Literature DB >> 9267642

Cat-301 immunoreactivity in the lateral geniculate nucleus and visual cortex of the strabismic amblyopic cat.

Z Q Yin1, S G Crewther, B Pirie, D P Crewther.   

Abstract

PURPOSE: It was investigated whether alterations in neuronal structure and function occasioned by strabismic amblyopia also may be reflected in alterations in the expression on Y type neurons of a Cat-301 antibody sensitive antigen in the lateral geniculate nucleus (LGN) and cortex of our cat model of strabismic amblyopia. METHODS/
RESULTS: The percentage of positively labelled cells was reduced in LGN laminae that received input from the deviated eye in strabismic amblyopic cats compared with normal cats. In the strabismic cortex, the density of immunopositive neurons was significantly reduced compared with normal the effect being most pronounced in layer IV.
CONCLUSIONS: Despite previous physiological recordings indicating a decrease in X-cell associated acuity in strabismic amblyopia, the present findings imply that the changes in the early visual experience occasioned by strabismus also produce specific molecular changes in the Y neuronal class.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267642     DOI: 10.1111/j.1442-9071.1997.tb01773.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  3 in total

1.  The contrast dependence of the cortical fMRI deficit in amblyopia; a selective loss at higher contrasts.

Authors:  Robert F Hess; Xingfeng Li; Guangming Lu; Benjamin Thompson; Bruce C Hansen
Journal:  Hum Brain Mapp       Date:  2010-08       Impact factor: 5.038

Review 2.  The role of eye movement driven attention in functional strabismic amblyopia.

Authors:  Hao Wang; Sheila Gillard Crewther; Zheng Qin Yin
Journal:  J Ophthalmol       Date:  2015-03-09       Impact factor: 1.909

3.  Deficient responses from the lateral geniculate nucleus in humans with amblyopia.

Authors:  Robert F Hess; Benjamin Thompson; Glen Gole; Kathy T Mullen
Journal:  Eur J Neurosci       Date:  2009-03       Impact factor: 3.386

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.